Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006

Objective. To evaluate health-related quality of life (HRQOL) and corticosteroid use in patients with moderate to severely active SLE enrolled in two international, multicentre, randomized controlled trials of epratuzumab (ALLEVIATE-1 and -2) and a long-term extension study (SL0006). Methods. Ninety...

Descripción completa

Detalles Bibliográficos
Autores principales: Strand, Vibeke, Petri, Michelle, Kalunian, Kenneth, Gordon, Caroline, Wallace, Daniel J., Hobbs, Kathryn, Kelley, Lexy, Kilgallen, Brian, Wegener, William A., Goldenberg, David M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2014
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3930886/
https://www.ncbi.nlm.nih.gov/pubmed/24273022
http://dx.doi.org/10.1093/rheumatology/ket378

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3930886/
https://www.ncbi.nlm.nih.gov/pubmed/24273022
http://dx.doi.org/10.1093/rheumatology/ket378

Ejemplares similares